Compare RDY & ENSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | ENSG |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.2B |
| IPO Year | 2001 | 2007 |
| Metric | RDY | ENSG |
|---|---|---|
| Price | $14.12 | $209.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $16.90 | ★ $202.60 |
| AVG Volume (30 Days) | ★ 1.7M | 319.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 0.50% | 0.12% |
| EPS Growth | N/A | ★ 14.06 |
| EPS | N/A | ★ 5.84 |
| Revenue | N/A | ★ $5,057,841,000.00 |
| Revenue This Year | $7.50 | $17.07 |
| Revenue Next Year | $2.96 | $9.49 |
| P/E Ratio | ★ $18.67 | $35.64 |
| Revenue Growth | N/A | ★ 18.72 |
| 52 Week Low | $12.26 | $118.73 |
| 52 Week High | $16.17 | $218.00 |
| Indicator | RDY | ENSG |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 57.27 |
| Support Level | $14.07 | $202.65 |
| Resistance Level | $14.14 | $217.46 |
| Average True Range (ATR) | 0.22 | 5.78 |
| MACD | -0.05 | -1.57 |
| Stochastic Oscillator | 16.05 | 48.96 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.